Literature DB >> 385399

A controlled comparative trial of mianserin and diazepam in the treatment of anxiety states in psychiatric out-patients.

L Conti, R M Pinder.   

Abstract

Forty psychiatric out-patients with primary anxiety entered a double-blind trial comparing 2 weeks of treatment with mianserin 30--60 mg daily or diazepam 15--30 mg daily, followed by 2 weeks of single-blind placebo administration. Both drugs were effective anti-anxiety agents, but mianserin was significantly superior in efficacy as measured by the Physician's Global Rating of Severity of Illness. No differences between treatments were apparent using the Hamilton Rating Scale for Anxiety. There was no significant differences in terms of side-effects and both drugs increased anticholinergic effects such as dry mouth, blurred vision and constipation over baseline values. With one exception in the mianserin group, all patients who entered placebo treatment became worse.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 385399     DOI: 10.1177/030006057900700405

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  4 in total

1.  5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model.

Authors:  G A Kennett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Mianserin and doxepin in the treatment of outpatient depression with anxiety.

Authors:  M C Khan; E H Bennie; S M Stulemeijer; M A Ravens
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety.

Authors:  G A Kennett; K Pittaway; T P Blackburn
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

4.  In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.

Authors:  G A Kennett; M D Wood; A Glen; S Grewal; I Forbes; A Gadre; T P Blackburn
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.